礼来公司口服GLP-1药物orforglipron帮助患者在从注射剂转用后保持体重下降，FDA的审查仍在等待中。 Eli Lilly's oral GLP-1 drug orforglipron helped patients maintain weight loss after switching from injectables, with FDA review pending.

Eli Lilly已宣布其口服GLP-1药物或forglipron的第3阶段试验结果为积极结果, 表明这有效地帮助病人在从注射药物Wegovy或Zepbound转换后保持体重下降。 Eli Lilly has announced positive Phase 3 trial results for its oral GLP-1 drug orforglipron, showing it effectively helps patients maintain weight loss after switching from injectable drugs Wegovy or Zepbound. 在这项首次的研究中,与安慰剂相比,转换为orforglipron的参与者在12个月内保持了大部分之前的减肥,重建的程度很小. In a first-of-its-kind study, participants who switched to orforglipron maintained most of their prior weight loss over 12 months, with minimal regain compared to placebo. 正在接受林业发展局审查的这一药物为有超重或肥胖症的成年人长期体重管理提供了方便的口服替代药物。 The drug, now under FDA review, offers a convenient oral alternative for long-term weight management in adults with overweight or obesity.